Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 11Neoplasm Metastasis 8Prostatic Neoplasms 6Triple Negative Breast Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 4Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Hematologic Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Liposarcoma 2Glioma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2

Interventions

Gemcitabine 4Oxaliplatin 3pembrolizumab 2tivozanib 1peposertib 1fludarabine 1durvalumab 1devimistat 1avelumab 1atezolizumab 1aldesleukin 1Temozolomide 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Pemetrexed 1Leucovorin 1Irinotecan 1Interleukin-2 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Capecitabine 1Cannabidiol 1Bortezomib 1Biopsy 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gallbladder Neoplasms × Biopsy × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡